KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy.

Naval Daver, Paresh Vyas, Gerwin Huls, Hartmut Döhner, Sébastien Maury, Jan Novak, Cristina Papayannidis, Carmen Martínez Chamorro, Pau Montesinos, Rabin Niroula, Pierre Fenaux, Jordi Esteve, Shang-Ju Wu, Adrien De Voeght, Jiri Mayer, Peter J M Valk, Lisa Johnson, Mei Dong, Ke Liu, Sowmya Kuwahara, Kenneth Caldwell, Guru Subramanian Guru Murthy

Blood 146(5) 601-611

PMID40233321
PMCIDPMC12824654
DOI10.1182/blood.2024027506
发表日期2025-04-15
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy (IC) have limited treatment options. The phase 3 ENHANCE-3 study aimed to determine whether magrolimab (magrolimab arm) was superior to placebo (control arm) when either was combined with venetoclax and azacitidine. Adults with previously untreated AML who were ineligible for IC were randomized to receive magrolimab (1 mg/kg on days 1 and 4, 15 mg/kg on day 8, 30 mg/kg on days 11 and 15, then weekly for 5 weeks, and then every 2 weeks) or placebo, venetoclax (100 mg on day 1, 200 mg on day 2, and 400 mg daily thereafter), and azacitidine (75 mg/m2 days 1-7) in 28-day cycles. The primary end point was overall survival (OS); key secondary end points included complete remission (CR) rate and safety. After randomization of 378 patients, the trial was stopped at a prespecified interim analysis owing to futility. At final analysis, with median follow-up of 7.6 months (magrolimab arm) vs 7.4 months (control arm), median OS was 10.7 vs 14.1 months (hazard ratio, 1.178; 95% confidence interval, 0.848-1.637). The CR rate within 6 cycles was 41.3% vs 46.0%. Addition of magrolimab to venetoclax and azacitidine resulted in more fatal adverse events (19.0% vs 11.4%), primarily driven by grade 5 infections (11.1% vs 6.5%) and respiratory events (2.6% vs 0%). There were similar incidences of any-grade infections, febrile neutropenia, and neutropenia between arms. These results highlight the difficulty in improving outcomes for patients with AML who were ineligible for IC. This trial was registered at www.clinicaltrials.gov as #NCT05079230.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 3.

EFS. IQR, interquartile range.

EFS_Kaplan-Meier_plot

Event-Free Survival (EFS)

Figure 3. · Panel EFS_Kaplan-Meier_plot

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel EFS_Kaplan-Meier_plot 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 2:short span曲线 2:extreme jump曲线 2:extreme upward reversal
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1无图注
非 KM Figure
Figure 1.CONSORT diagram. ∗Lack of efficacy (n = 4), protocol violation (n = 1), and initiation of anti-AML therapy (n = 1). † Lack of efficacy (n = 6) and patient never exposed to study drug (n = 5). CONSORT, Consolidated Standards of Reporting Trials; SCT, stem cell transplantation.
非 KM Figure
Figure 2.OS (final analysis). ∗Stratified 2-sided P value shown.
非 KM Figure